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The four dengue virus (DENV) serotypes, DENV-1, -2, -3, and -4, are
endemic throughout tropical and subtropical regions of the world,
with an estimated 390 million acute infections annually. Infection
confers long-term protective immunity against the infecting sero-
type, but secondary infection with a different serotype carries a
greater risk of potentially fatal severe dengue disease, including
dengue hemorrhagic fever and dengue shock syndrome. The single
most effective measure to control this threat to global health is
a tetravalent DENV vaccine. To date, attempts to develop a pro-
tective vaccine have progressed slowly, partly because the targets
of type-specific human neutralizing antibodies (NAbs), which are
critical for long-term protection, remain poorly defined, imped-
ing our understanding of natural immunity and hindering effective
vaccine development. Here, we show that the envelope glycopro-
tein domain I/II hinge of DENV-3 and DENV-4 is the primary target of
the long-term type-specific NAb response in humans. Transplanta-
tion of a DENV-4 hinge into a recombinant DENV-3 virus showed
that the hinge determines the serotype-specific neutralizing potency
of primary human and nonhuman primate DENV immune sera and
that the hinge region both induces NAbs and is targeted by
protective NAbs in rhesus macaques. These results suggest that
the success of live dengue vaccines may depend on their ability to
stimulate NAbs that target the envelope glycoprotein domain I/II
hinge region. More broadly, this study shows that complex
conformational antibody epitopes can be transplanted between live
viruses, opening up similar possibilities for improving the breadth
and specificity of vaccines for influenza, HIV, hepatitis C virus, and
other clinically important viral pathogens.
infectious clone | neutralizing antibody
The four dengue virus serotypes (DENV-1, -2, -3, and -4),transmitted by Aedes spp. mosquitoes, are endemic through-
out tropical and subtropical regions of the world, with an esti-
mated 390 million new infections annually (1). Primary infection
with one serotype confers long-term immunity against that sero-
type, but repeat infection with a different serotype has an in-
creased risk of potentially fatal severe dengue disease (2), including
dengue hemorrhagic fever and dengue shock syndrome. This risk
has been attributed, at least in part, to the ability of some cross-
reactive antibodies to enhance infection of Fc-receptor bearing
cells. The consensus is that, to be safe and effective, any dengue
vaccine must simultaneously induce neutralizing antibodies (NAbs)
to all four serotypes. However, DENV vaccine development has
progressed slowly, highlighted by the disappointing results of the live-
attenuated Sanofi Pasteur tetravalent DENV vaccine trial in Thai-
land (3). Progress is hindered, in part, because the epitopes targeted
by the type-specific human NAbs critical for long-term protection
(4, 5) remain poorly defined, limiting our understanding of natural
DENV immunity and slowing effective vaccine development.
The DENV envelope glycoprotein (E) (Fig. 1A) is the major
surface-exposed DENV antigen and the principle target of NAbs.
The E structure consists of three distinct domains: I, II, and III
(EDI, EDII, and EDIII) (6, 7); EDIII is a continuous peptide
extending from domain I and forming an Ig-like fold, whereas EDI
and EDII are discontinuous and connect by four peptide linkers
that form the EDI/EDII hinge. We and others have recently de-
scribed potent human DENV NAbs that bind to epitopes around
the EDI/EDII hinge (8, 9). To more fully explore the significance
of this antigenic region, we used reverse genetics and synthetic
biology to transplant the EDI/EDII antigenic region from DENV-
4 into a DENV-3 background and showed by both gain- and loss-
of-function assays that the EDI/EDII hinge region is the primary
target of the long-lived DENV serotype-specific NAb response.
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Defining the EDI/EDII Hinge. To more fully explore the significance
of the EDI/EDII region, we examined the epitope target of the po-
tently neutralizingDENV-3–specific humanmonoclonalNAb5J7 (8,
10), which was recovered from a donor (donor 105) previously
infected with DENV-3. To identify the 5J7 epitope, we generated
a comprehensive library of DENV-3 E proteins, in which every res-
idue was separately mutated (1,400 total mutants). Variant E pro-
teins were expressed individually, and the effect of the point
mutations on 5J7 binding to E was analyzed, identifying seven
critical residues—Q52, L53, E126, K128, E133, L135, and A203
(Fig. 1 A and C)—all localized to the EDI/EDII hinge region.
As a complementary approach, we also passaged DENV-3 in the
presence of high concentrations of 5J7 to generate viral escape
mutants; we identified three escape mutations—Q269K270ins_K
(8), L53P, and K128G (Fig. 1A andC)—that are also all localized to
theEDI/EDII hinge region.When subsequently tested against donor
105 polyclonal serum, the virus containing the Q269K270ins_K
mutation showed a statistically significant 78%drop in neutralization
titer (from 1:379 to 1:83; P < 0.05, ANOVA followed by Dunnett
test) (SI Appendix, Fig. S1). One potential explanation for the sig-
nificant drop in titer is that multiple DENV-3 NAbs in human
polyclonal serum target epitopes within the EDI/EDII hinge region.
Construction and Characterization of the Recombinant EDI/EDII Hinge
Transplant Virus Recombinant DENV-3/4: Long-Lived Neutralization
Responses Against Primary DENV Infections Are Specific to the
Serotype Of Infection. To test the hypothesis that the EDI/EDII
hinge region is a major target of the human polyclonal neutraliza-
tion response after primary infection, we first visualized the 5J7
Fig. 1. (A) Cartoon representation of the DENV-3 E
dimer with EDI (red), EDII (yellow), and EDIII (blue). The
EDI/EDII hinge region is circled. Location of the critical
residues associated with escape mutations and muta-
genesis-mapped 5J7 residues are shown. Residues
critical for 5J7 binding identified by shotgun muta-
genesis loss of binding of E glycoprotein expressed in
HEK-293T cells are shown in magenta. Mutations as-
sociated with both viral escape from 5J7 and loss of
binding in HEK-293T cells (L53 and K128) are shown in
orange, and the single residue identified by escape
mutation alone (Q269K270_insK) is shown in cyan. All
critical residues were individually identified but are
shown on a single E dimer for simplicity. (B) Cartoon
representation of the DENV E dimer with the locations
of variable EDI/EDII hinge residues transplanted be-
tween rDENV-3 and rDENV-4 to make rDENV-3/4 shown
in green. (C) Primary sequence alignment and second-
ary structure of rDENV-3 E, rDENV-3/4 E, and rDENV-4 E.
Secondary structure is indicated above the primary se-
quence and color-coded to the corresponding domains
on the tertiary structure (A and B). Arrows indicate
β-sheets, cylinders indicate helices, and lines indicate
spanning loops and strands. Binding, escape, and hinge
residues shown in A and B are indicated by corresponding
colors in the rDENV-3 sequence. Amino acid residues
transplanted between rDENV-3/4 and rDENV-4 are in-
dicated in green for both sequences.
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epitope footprint on the DENV-3 E structure (11) by identifying
all amino acid residues within 12 Å (i.e., the approximate foot-
print of an antibody paratope) of the most central escape mu-
tation—K128G. Our intent was to then probe the contribution of
this region to polyclonal serum neutralization by extensively
mutating it in a DENV-3 infectious clone background (12).
Because the EDI/EDII hinge region must remain flexible over
the course of DENV infection (13), we replaced the EDI/EDII
hinge in a DENV-3 infectious clone with amino acids from the
corresponding structures of the DENV-4 EDI/EDII hinge (Fig. 1
B and C). Our hypothesis was that transplanting DENV-4 EDI/
EDII hinge residues into the DENV-3 E protein would maintain
short-range residue interactions critical to E-protein hinge func-
tion but transfer the DENV-4 EDI/EDII hinge serotype-specific
epitopes. The resultant recombinant DENV-3/4 hinge virus
(rDENV-3/4) contained 25 amino acid changes, showed sim-
ilar growth kinetics to parental rDENV-3 in Vero and C6/36
insect cells (SI Appendix, Fig. S2), showed similar plaque pheno-
types in Vero cells (SI Appendix, Fig. S3), and similarly bound E-
specific mAbs that target E epitopes outside the EDI/EDII hinge
(SI Appendix, Fig. S4); collectively, these findings show that EDI/
EDII hinge function and E tertiary structure were preserved in the
chimeric virus.
Transplantation of DENV-4 EDI/EDII Hinge into DENV-3 Leads to Loss
of Neutralization by DENV-3 Primary Sera. To assess the impact of
EDI/EDII hinge transplantation on polyclonal antibody neu-
tralization, a panel of human (SI Appendix, Table S1) and rhesus
macaque (RM) primary DENV-3 convalescent antisera collected
>1 y after infection (14) was screened against the parental
rDENV-3, rDENV-4, and rDENV-3/4 viruses (Fig. 2). Primary
DENV-3 sera potently neutralized DENV-3 and weakly neu-
tralized DENV-4 (Fig. 2 A and B). Remarkably, rDENV-3/4
hinge was rendered insensitive to neutralization by human and
primate primary DENV-3 sera (P < 0.05), with a neutralization
profile equivalent to DENV-4 sera (Fig. 2 A and B). This near-
complete loss of sensitivity to neutralization by primary DENV-3
sera supports the model that the EDI/EDII hinge region contains
most or all of the epitope determinants of serotype specificity
after natural DENV infection.
Transplantation of DENV-4 EDI/EDII Hinge into DENV-3 Leads to Gain
of Neutralization by DENV-4 Primary Sera. If serotype-specific
epitopes at the EDI/EDII hinge are the target of human
antibodies that neutralize DENV-4 as well, successful trans-
plantation of the DENV-4 EDI/EDII hinge into rDENV-3
should render rDENV-3/4 sensitive to neutralization by pri-
mary DENV-4 serum. We then tested rDENV-3, rDENV-4, and
rDENV-3/4 virus in neutralization assays against a panel of human
(SI Appendix, Table S2) and RM primary DENV-4 antisera (14).
All eight sera effectively neutralized DENV-4 and had much lower
neutralization titers against rDENV-3 (Fig. 2 C and D). Signifi-
cantly, rDENV-3/4 was sensitive to neutralization by DENV-4
antisera, gaining >95% of the DENV-4 neutralizing phenotype for
all sera tested. This gain of function or sensitivity to neutralization
with the EDI/EDII hinge region transplant strongly supports the
model that the EDI/EDII region defines the epitopes critical for
serotype-specific neutralization after natural DENV infection.
EDI/EDII Hinge Directs Antibody-Dependent Enhancement in a Serotype-
Specific Manner. In secondary DENV infections, cross-reactive
non-NAbs from the first infection are thought to contribute to
severe disease pathogenesis by Fc receptor-mediated uptake of
antibody-bound virus into target cells, a phenomenon called an-
tibody-dependent enhancement (ADE) (15, 16). To test if EDI/
EDII hinge transplantation altered human immune sera en-
hancement in Fc receptor-bearing cells, rDENV-3, rDENV-4,
and rDENV-3/4 viruses were characterized in a K562 cell-based
ADE assay using primary human DENV-immune sera (17). As
expected, when rDENV-3 or rDENV-4 was incubated with
physiologically relevant high concentrations of primary sera from
each serotype, each virus was enhanced by heterologous but not
homologous immune sera (Fig. 3 and SI Appendix, Fig. S5). Thus,
at high serum concentrations approximating the levels circulating
in people, rDENV-3/4 virus was enhanced by DENV-3 but not
DENV-4 immune sera, indicating that the EDI/EDII hinge
transplant altered the ADE profile of DENV-3 to a profile sim-
ilar to DENV-4. When a serum sample had high levels of NAbs
to a particular virus (rDENV-3 with primary DENV-3 immune
sera), we did not observe enhancement at high serum concen-
trations (Fig. 3). When NAbs are diluted to subneutralizing levels,
they are capable of enhancement (SI Appendix, Fig. S5), which is
Fig. 2. FRNT50 values for the parental rDENV-3 infectious clone, parental rDENV-4, and rDENV-3/4 against human and RM primary DENV-3 and DENV-4
immune sera. Each panel shows results for a single donor or RM. The y axis shows serum fold dilution that neutralized 50% of input virus on a log scale. The x
axis shows input virus. (A) Four late convalescent primary DENV-4 human primary neutralization titers. Each graph shows one individual. (B) Four convalescent
(24 mo postinfection) RM primary DENV-3 neutralization titers. (C) Four late convalescent primary DENV-4 human primary neutralization titers. (D) Four
convalescent (24 mo postinfection) RM primary DENV-4 neutralization titers. Error bars show 95% confidence intervals. *FRNT50 was <1:20.

















unlikely to be of any biological significance at these physiologi-
cally irrelevant dilutions of serum.
EDI/EDII Hinge Directs a Type-Specific Immune Response After Primary
Infection. Primates are the only known vertebrate hosts of
DENVs. To study replication and the immunogenic properties
of rDENV-3/4 in vivo, we inoculated four dengue-naïve RMs
with 5 × 105 focus forming units (FFUs) virus and followed the
animals for viral infection. The RMs did not develop disease
but did become viremic for a mean of 4.25 ± 0.957 d (Table 1),
similar to days viremia reported for WT DENV at similar doses
in RMs (14). At 60 d after rDENV-3/4 inoculation, DENV-4
focus reduction neutralization test (FRNT50) titers were approxi-
mately four- to sixfold higher than titers against the other three
serotypes (Table 1). This early convalescent response is consistent
with our hypothesis that the EDI/EDII hinge directs serotype-
specific neutralization in vivo. It is well-established that RMs ex-
posed to primary DENV infections are protected from repeat
infections with the same serotype, while remaining susceptible to
secondary infections with new serotypes (18, 19).
NAbs Targeting the EDI/EDII Are Sufficient to Protect Against DENV
Infection. To test whether NAbs targeting the EDI/EDII hinge
are sufficient to protect RMs against heterotypic DENV chal-
lenge, RMs exposed to primary DENV-4 infections 2 y before
(14) were challenged with rDENV-3/4. Heterotypic challenge in
primary immune RMs has been previously shown to result in
detectable viremia with a duration of 1–4 d (18, 19). In this
challenge, all four animals were protected completely from de-
tectable rDENV-3/4 viremia (Table 1), although serum DENV
FRNT50 titers were significantly boosted (DENV-3 geometric
mean titer for all animals, 1:1,135; DENV-4 geometric mean
titer, 1:5,531) (Table 1). Because the only DENV-4–specific
antigen in rDENV-3/4 was the hinge region itself, this result
strongly suggests that long-lived NAbs that target the EDI/EDII
hinge are a major component of protective immunity in vivo.
Discussion
DENV infection typically results in a short-lived broad neutrali-
zation response that matures over time into a serotype-specific
neutralization response. Results presented here show that the
EDI/EDII hinge region is the principle target of long-lived sero-
type-specific NAbs that develop in humans after natural DENV-3
and DENV-4 infections. Moreover, experimental challenge studies
in RMs with the rDENV-3/4 chimera show that the hinge region
elicits a serotype-specific NAb response in vivo and strongly sug-
gest that hinge Abs protect against viremia in vivo, although the
boosted antibody titers 28 d postchallenge suggest that undetected
viral replication may have occurred. The hinge has been shown to
play a critical role in the conformational change that E protein
undergoes at low pH to fuse with cellular endosomes, allowing
viral uncoating and the release of viral RNA into the cellular
Fig. 3. Antibody-dependent enhancement of
rDENV-3, rDENV-3/4, and rDENV-4 viruses by human
primary sera in K562 cells. K562 cells are Fc receptor-
bearing cells that are minimally permissive to DENV
infection in the absence of antibody, but in the
presence of antibody, they become permissive to in-
fection through Fc-mediated endocytosis. The x axis
indicates serum tested. The y axis shows percent of
K562 cells infected with DENV at 1:20 serum dilution,
which was measured by flow cytometry. P values
were computed for unpaired Student t tests using
GraphPad Prism, v.6.0b. (A) DENV-1 primary sera, (B)
DENV-2 primary sera, (C) DENV-3 primary sera, and
(D) DENV-4 primary sera. Error bars show SEM.






Viremia (log FFU/mL) days
postchallenge
Days
viremia DENV-1 DENV-2 DENV-3 DENV-4DENV-3 DENV-4 1 2 3 4 5 6 7
60-d Postchallenge FRNT50 titer
2L7 Naïve <1:20 <1:20 2.3 2.7 2.8 1.1 1.1 ND ND 5 1:106 1:160 1:343 1:1,536
2L2 Naïve <1:20 <1:20 2.7 3.5 1.7 1.1 ND ND ND 4 1:269 1:99 1:196 1:1,266
9K8 Naïve <1:20 <1:20 1.9 2.1 1.8 2.3 1.1 ND ND 5 1:44 1:95 1:167 1:616
9L4 Naïve <1:20 <1:20 1.6 2.4 1.1 ND ND ND ND 3 1:107 1:112 1:224 1:1,047
28-d Postchallenge FRNT50 titer
BD57 1° DENV-4 <1:20 1:263 ND ND ND ND ND ND ND 0 1:70 1:112 1:1,248 1:10,197
9G9 1° DENV-4 1:35 1:149 ND ND ND ND ND ND ND 0 1:90 1:129 1:734 1:7,147
6G0 1° DENV-4 <1:20 1:146 ND ND ND ND ND ND ND 0 1:36 1:41 1:1,163 1:2,897
6F8 1° DENV-4 <1:20 1:286 ND ND ND ND ND ND ND 0 1:94 1:273 1:1,559 1:5,814
ND, not detected.
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cytoplasm (7). We hypothesize that hinge-targeting NAbs act
through mechanisms that block this structural transition, con-
sistent with what has been reported for West Nile virus (20, 21).
Our data are consistent with models where the EDI/EDII
hinge of each serotype contains a single or multiple overlapping
epitopes targeted by primate NAbs. Indeed, structure studies
with human mAbs that bind to the EDI/EDII hinge region of
flaviviruses indicate that this region contains overlapping qua-
ternary epitopes (9, 20). Although primary cross-reactive T-cell
responses and antibodies do not confer long-term protection
against heterologous challenge in primates, it is possible that the
EDI/EDII hinge region contains peptides that can be recognized
by DENV-specific T cells that also contribute to protection
against DENV reinfection. We feel this explanation is less likely
given that the most extensive survey of DENV T cell-specific
epitopes in humans did not identify any E hinge epitopes among
the 25 most immunodominant regions of the DENV proteome
(22). Clearly, additional primate challenge and protection stud-
ies in different DENV immune backgrounds are needed to more
fully decipher the roles of hinge-independent type-specific and
cross-protective immunity in vivo and the extent to which changes
in epitope display outside the EDI/EDII hinge region also impact
antibody recognition of the DENV E glycoprotein.
These results have important implications for development of
DENV vaccines. The leading DENV vaccines are live-attenuated
flaviviruses expressing DENV E proteins (23). Our results in-
dicate that the success of these live flavivirus vaccines may de-
pend on their ability to elicit antibodies that target the EDI/EDII
hinge region. Not only will recombinant virus reagents allow us to
measure EDI/EDII hinge-specific responses, but our results also
provide a basis for designing epitope mimetic peptide vaccines
that stimulate serotype-specific NAbs and not the cross-reactive
antibodies with potential for disease enhancement. More broadly,
our demonstration that complex conformational antibody epito-
pes can be transplanted between live viruses with minimal impacts
on growth in vitro and in vivo opens up possibilities for improving
vaccine breadth and specificity in other important human viral
pathogens with known complex NAb epitopes, including hepa-
titis C virus (24), influenza (25), and HIV (26).
Materials and Methods
Cells. Mosquito Ae. albopictus C6/36 cells were maintained in MEM (Gibco)
media at 32 °C. Human monocyte lymphoma cell line U937 expressing DC-
SIGN (U937 DC-SIGN) was maintained in RPMI-1640 (Gibco) at 37 °C sup-
plemented with 50 mM β-mercaptoethanol. Vero-81 cells were maintained
in DMEM at 37 °C. All media used were also supplemented with 5% (vol/vol)
FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, 0.1 mM nonessential
amino acids (Gibco), and 2 mM glutamine, and all cells were incubated in the
presence of 5% CO2. The 5% FBS was reduced to 2% to make infection
media for each cell line.
ADE Assays. Antibody-dependent enhance assays were conducted as pre-
viously described (17) and adopted for K562 cells. Briefly, polyclonal serum
samples were diluted twofold from 1:20 and incubated for 1 h at 37 °C with
rDENV-3, rDENV-3/4, or rDENV-4. K562 cells (5 × 104 cells/well) were added to
the antibody–virus mixture and incubated for an additional 2 h at 37 °C.
After the 2-h incubation, cells were washed two times with infection media
and incubated overnight at 37 °C and 5% CO2. Twenty-four hours after in-
fection, cells were washed, fixed, stained for DENV structural proteins with
mAb 4G2, and percent infection-assessed on an EMD Millipore Guava
Flow Cytometer.
Binding ELISA. Equal virus quantities of DENV-3 and rDENV-3/4 (as previously
titrated by ELISA) were captured using amixture of coated anti-prM and anti-
E antibodies. The capture antibodies used were either mouse or human
depending on the species of the primary antibody being tested. The primary
antibodies, 4G2 (mouse mAb) and 1N5 and 5J7 (human mAbs), were di-
luted fourfold from 10 to 0.002 μg/mL. Alkaline phosphatase-conjugated
secondary antibodies were used to detect binding of primary antibodies
with a P-nitrophenyl phosphate substrate, and color change was quan-
tified with spectrophotometry.
Shotgun Mutagenesis Epitope Mapping. A DENV-3 prM/E expression construct
(DENV-3 strain CH53489) was subjected to high-throughput mutagenesis
(shotgun mutagenesis) to generate a comprehensive mutation library (27).
Point mutations were introduced into the DENV-3 prM/E polyprotein by PCR
using a Diversity Mutagenesis Kit (Clontech Laboratories, Inc.). In total,
1,400 DENV-3 mutants were generated (>97% coverage of the prM/E ecto-
domain), sequence confirmed, and arrayed into 384-well plates (one mu-
tation per well). Each E mutant was individually transfected into HEK-293T
cells and allowed to express for 22 h. Cells were fixed in 4% (wt/vol)
paraformaldehyde (Electron Microscopy Sciences) and permeabilized with
0.1% (wt/vol) saponin (Sigma-Aldrich) in PBS plus calcium and magnesium
(PBS++). Cells were stained with purified 5J7 antibody (0.2 μg/mL) diluted
in 10% normal goat serum (NGS) (Sigma)/0.1% saponin (pH 9). The optimal
primary antibody concentration was determined using an independent
immunofluorescence titration curve against WT prM/E to ensure that signals
were within the linear range of detection and that signal exceeded back-
ground by at least fivefold. Antibody binding was detected using 3.75 μg/mL
AlexaFluor488-conjugated secondary antibody (Jackson ImmunoResearch
Laboratories) in 10% NGS/0.1% saponin. Cells were washed three times, and
mean cellular fluorescence was detected using an Intellicyt High-Throughput
Flow Cytometer (Intellicyt). Antibody reactivities against each mutant Env
clone were calculated relative to WT Env protein reactivity by subtracting
the signal from mock-transfected controls and normalizing to the signal
from WT Env-transfected controls for the serotype tested. Mutations within
critical clones were identified as critical to the MAb epitope if they did not
support reactivity of the test MAb but did support reactivity of other anti-
bodies. This counterscreen strategy facilitates the exclusion of Env mutants
that are locally misfolded or have an expression defect (28). Critical amino
acids required for antibody binding were visualized on the DENV Env crystal
structure (Protein Data Bank ID code 1UZG) (11).
DENV Infectious Clones. The four-fragment cloning strategy for the recombinant
parental rDENV-3 clone was recently described (12). rDENV-4 [submitted to
GenBank (submission no. 1683917)] was constructed in a similar manner. In
brief, cDNAs were transcribed from a clinical DENV-3 and DENV-4 isolated and
subcloned as four separate DNA fragments into stable plasmids (A–D). Primers
were used to introduce a T7 promoter at the 5′ end of the A fragment and
unique type IIS restriction sites at the 5′ and 3′ ends of each of the other
fragments as follows: rDENV-3: A fragment, SpeI + BsmBI; B fragment, BsmBI +
BglI; C fragment, BglI + BglI; D fragment, BglI + BsmBI; rDENV-4: A fragment,
SpeI + PflmI; B fragment, PflmI + DraIII; C fragment, DraIII + PflmI; D fragment,
PflmI_BsmbI. The rDENV-4 A–B fragment junction is at genomic nucleotide
positions 3185/3186, the B–C junction is at positions 5458/5459, and the C–D
junction is at positions 8832/8833. Plasmids were propagated in Escherichia coli,
purified, restriction enzyme-digested with type IIS restriction enzymes, and
directionally ligated with T4 DNA ligase to create a full-length cDNA of the
dengue viral genome. The cDNAs were subsequently transcribed with T7
polymerase. This RNA produced infectious dengue virus when electroporated
into Vero E6 cells.
The EDI/EDII hinge residues are encoded exclusively on the A fragment. To
generate rDENV-3/4, the nucleotides encoding the DENV-3 EDI/EDII hinge
amino acids were replaced with nucleotides encoding the DENV-4 hinge, and
a new A fragment containing the nucleotide substitutions was synthesized
and inserted into plasmid pUC-57 (BioBasic). Plasmid was propagated in
E. coli, purified, digested, ligated, and transcribed as previously described
(12). Electroporation of recombinant RNA into Vero E6 cells led to recovery
of viable recombinant rDENV-3/4. All infectious clones were subsequently
passaged one or two times in C6/36 cells, and cell culture supernatants were
clarified, supplemented with 20% FBS, and stored at −80 °C.
DENV Immune Sera. Human DENV immune sera were collected from either
adult volunteers with histories of DENV infection (29) or anonymous blood
donors, or they were provided from a pool of previously characterized DENV
immune sera. Sera were initially characterized by flow cytometry at the
University of North Carolina (30), FRNT50 at the University of North Carolina,
plaque reduction neutralization test (PRNT60) at the National Institutes of
Health, or PRNT90 at the Centers for Disease Control and Prevention San
Juan to confirm past DENV exposure and also, identify the serotype re-
sponsible for primary infections.
Virus Titration and FRNT. The FRNT procedure is based on a method previously
described by Durbin et al. (31). Briefly, 24-well plates were seeded with 5 × 104

















Vero cells in MEM supplemented with 5% FBS and grown for 24 h. Growth
media were removed. For virus titration, virus stocks were diluted serially 10-
fold and added to individual wells. Cells were overlaid with 1 mL 0.8%
methylcellulose in OptiMEM (Gibco) supplemented with 2% FBS (Cellgro) and
antibiotic mix (Gibco Anti-Anti), and they were incubated for 5 d at 37 °C and
5% CO2. On day 5, overlay was removed, and cells were washed with PBS,
fixed in 80% methanol, and developed. To develop plates, fixed monolayers
were blocked with 5% instant milk PBS followed by incubation with anti-
flavivirus MAb 4G2 diluted 1:1,000. Wells were washed with PBS and in-
cubated with HRP-conjugated goat anti-mouse Ab (Sigma) diluted 1:500 in
blocking buffer for 1 h at 37 °C. Plates were washed one time in PBS, and foci
were developed by the addition of 100 μL TrueBlue HRP substrate (KPL). Foci
were counted on a light box, and viral titers were calculated by standard
methods. For FRNT, mAbs or human sera were serially diluted fourfold from
starting dilutions of 1:10 or 1:20. Each dilution was mixed with ∼50 FFUs virus
to a final volume of 200 μL, incubated for 1 h at 37 °C and 5% CO2, added in
triplicate to 24-wells plates, and processed as above. Mean focus diameter was
calculated from ≥20 foci/clone measured at 5× magnification.
RM Infection and Challenge.All animals were housed at the Caribbean Primate
Research Center facilities. Four young adult RMs (2–4 y of age) seronegative
for dengue virus were used as controls (2L7, 2L2, 9K8, and 9L4), and four
animals previously exposed to DENV-4 24 mo before (14) were used as the
experimental group (6G0, 9G9, BD57, and 6F0). All animals were challenged
s.c. with 5 × 105 FFUs rDENV-3/4, and then, they were bled every day for 10 d
postchallenge and days 30 and 60 after challenge. All animals’ procedures
were reviewed and approved by the Animal Care and Use Committee at the
Medical Sciences Campus, University of Puerto Rico and performed in a
facility fully accredited by the Association for Assessment and Accredita-
tion of Laboratory Animal Care (Animal Welfare Assurance Number: A3421,
protocol number: 7890113). In addition, steps were taken to ameliorate
suffering in accordance with the recommendations of the Weatherall re-
port, “The Use of Non-Human Primates in Research.” During the time of the
protocol, animals were under the Environmental Enrichment Program of
the facility, which was also approved by the University of Puerto Rico In-
stitutional Animal Care and Use Committee.
Software and Statistics. Multiple alignments were performed using ClustalX
version 1.83 (32). The structural model of the hinge epitope region was
generated using MacPymol (Delano Scientific) and the crystal structure of
DENV-3 envelope (Protein Data Bank ID code 1UZG) (6). Alignments and
secondary structure figures were generated using ALINE (33). FRNT counts
were entered into Graphpad Prism (Version 5.00 for OSX; GraphPad Soft-
ware). FRNT50 values were calculated by sigmoid dose–response curve fit-
ting, with upper and lower limits of 100 and 0, respectively. All error bars
show 95% confidence intervals unless otherwise specified.
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